CRVO Cervomed announces new clinical, plasma biomarker and Imaging data at aaic 2026 for neflamapimod in the treatment of dementia with lewy

CRVO Cervomed announces new clinical, plasma biomarker and Imaging data at aaic 2026 for neflamapimod in the treatment of dementia with lewy bodies (dlb)